Acupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's disease

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Kim, Seung Nam ^a   Doo, Ah Reum ^a   Park, Ji Yeun ^a   Bae, Hyungjin ^a   Chae, Younbyoung ^a   Shim, Insop ^a   Lee, Hyangsook ^a   Moon, Woongjoon ^a   Lee, Hyejung ^a   Park, Hi Joon ^a  

^a Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; PHOSPHOPROTEIN DARPP 32; TRANSCRIPTION FACTOR FOSB; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FOSB PROTEIN, MOUSE; PROTEIN C FOS;

ACUPUNCTURE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; MALE; MOTOR PERFORMANCE; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POSTSYNAPTIC POTENTIAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THERAPY EFFECT; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; METABOLISM; MOTOR ACTIVITY; NEOSTRIATUM; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SYNAPSE; TIME;

ANIMALIA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACUPUNCTURE POINTS; ACUPUNCTURE THERAPY; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MOTOR ACTIVITY; NEOSTRIATUM; NERVE DEGENERATION; PARKINSON DISEASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; SYNAPSES; TIME FACTORS;

EID: 81555207952     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027566     Document Type: Article

References (36)

1. Fahn S, (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991: 1-14.
2. Mouradian MM, Juncos JL, Serrati C, Fabbrini G, Palmeri S, et al. (1987) Exercise and the antiparkinsonian response to levodopa. Clin Neuropharmacol 10: 351-355.
3. Jeon S, Kim YJ, Kim ST, Moon W, Chae Y, et al. (2008) Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model. Proteomics 8: 4822-4832.
4. Liang XB, Luo Y, Liu XY, Lu J, Li FQ, et al. (2003) Electro-acupuncture improves behavior and upregulates GDNF mRNA in MFB transected rats. Neuroreport 14: 1177-1181.
5. Park HJ, Lim S, Joo WS, Yin CS, Lee HS, et al. (2003) Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model. Exp Neurol 180: 93-98.
6. Kim S-N, Kim S-T, Doo A-R, Park J-Y, Moon W, et al. (2011) The phosphatidylinositol 3-kinase/Akt signalling pathway mediates acupuncture-induced improvements in a mouse model of Parkinson's disease. Int J Neurosci (in press).
7. Kang JM, Park HJ, Choi YG, Choe IH, Park JH, et al. (2007) Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. Brain Res 1131: 211-219.
8. Kim ST, Moon W, Chae Y, Kim YJ, Lee H, et al. (2009) The effect of electroaucpuncture for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced proteomic changes in the mouse striatum. J Physiol Sci 60: 27-34.
9. Yu YP, Ju WP, Li ZG, Wang DZ, Wang YC, et al. (2010) Acupuncture inhibits oxidative stress and rotational behavior in 6-hydroxydopamine lesioned rat. Brain Res 1336: 58-65.
10. Liangyue D, Yijun G, Shuhui H, Xiaoping J, Yang L, et al. (2004) Chinese Acupuncture and Moxibustion Beijing Foreign Language Press.
11. Jeun SS, Kim JS, Kim BS, Park SD, Lim EC, et al. (2005) Acupuncture stimulation for motor cortex activities: a 3T fMRI study. Am J Chin Med 33: 573-578.
12. Na BJ, Jahng GH, Park SU, Jung WS, Moon SK, et al. (2009) An fMRI study of neuronal specificity of an acupoint: electroacupuncture stimulation of Yanglingquan (GB34) and its sham point. Neurosci Lett 464: 1-5.
13. World.Health.Organization (2008) WHO Standard Acupuncture Point Locations in the Western Pacific Region Manila WHO Regional Office for the Western Pacific.
14. Yin CS, Jeong HS, Park HJ, Baik Y, Yoon MH, et al. (2008) A proposed transpositional acupoint system in a mouse and rat model. Res Vet Sci 84: 159-165.
15. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL, (1998) The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 83: 165-175.
16. Rozas G, Guerra MJ, Labandeira-Garcia JL, (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2: 75-84.
17. Keith BJ, Franklin GP, (2008) The Mouse Brain in Stereotaxic Coordinates California Academic.
18. Hirsch EC, Faucheux BA, (1998) Iron metabolism and Parkinson's disease. Mov Disord 13 (Suppl 1): 39-45.
19. Hirsch EC, Hunot S, Damier P, Faucheux B, (1998) Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 44: S115-120.
20. Santini E, Valjent E, Fisone G, (2008) Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 275: 1392-1399.
21. Greengard P, Allen PB, Nairn AC, (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23: 435-447.
22. Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, et al. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 23: 4081-4091.
23. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, et al. (2007) Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27: 3328-3337.
24. Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, et al. (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 13650-13655.
25. Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, et al. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28: 10460-10471.
26. Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, et al. (2007) Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci 27: 5291-5300.
27. Vuckovic MG, Wood RI, Holschneider DP, Abernathy A, Togasaki DM, et al. (2008) Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 32: 319-327.
28. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, et al. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255.
29. Tseng JL, Baetge EE, Zurn AD, Aebischer P, (1997) GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J Neurosci 17: 325-333.
30. Jia J, Li B, Sun ZL, Yu F, Wang X, et al. (2010) Electro-acupuncture stimulation acts on the basal ganglia output pathway to ameliorate motor impairment in Parkinsonian model rats. Behav Neurosci 124: 305-310.
31. Robertson GS, Robertson HA, (1989) Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9: 3326-3331.
32. Cheramy A, Leviel V, Glowinski J, (1981) Dendritic release of dopamine in the substantia nigra. Nature 289: 537-542.
33. Jia J, Sun Z, Li B, Pan Y, Wang H, et al. (2009) Electro-acupuncture stimulation improves motor disorders in Parkinsonian rats. Behav Brain Res 205: 214-218.
34. Andersson M, Hilbertson A, Cenci MA, (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6: 461-474.
35. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, et al. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6: 501-506.
36. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH, (2009) A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 8: 929-937.